ACM
BBIO icon

Atika Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Atika Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,720
Closed -$4.36M – 88
2024
Q2 		$4.36M Hold
1,720
– – 0.43% 67
2024
Q1 		$5.32M Buy
+1,720
New +$58.5K 0.52% 65
2023
Q2 		– Sell
-1,020
Closed -$1.69M – 85
2023
Q1 		$1.69M Buy
+1,020
New +$11.9K 0.25% 70

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atika Capital Management's BBIO Position: Q1 2026 in Review

Atika Capital Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 35,200 shares worth $2.61M. The stake represents 0.33% of the portfolio and ranks #58 among its holdings. This is a return to the name: Atika Capital Management previously reported a position in BBIO as recently as Q4 2023.

Atika Capital Management first reported a position in BBIO in Q4 2019 and has held it in 11 quarters since. The position peaked at $5.04M in Q4 2020. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Atika Capital Management held 35,200 shares of BridgeBio Pharma worth $2.61M as of Q1 2026.
  • BridgeBio Pharma was a new Atika Capital Management position in Q1 2026.
  • BridgeBio Pharma made up 0.33% of Atika Capital Management's portfolio in Q1 2026, its #58 holding.
  • Atika Capital Management first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 11 quarters since.
  • Atika Capital Management's BridgeBio Pharma position peaked at $5.04M in Q4 2020.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.